The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
 
Evan P. Pisick
No Relationships to Disclose
 
Elizabeth Garrett-Mayer
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie
Consulting or Advisory Role - Deciphera; Okava Pharmaceuticals; Tactical Therapeutics; TYME
 
Susan Halabi
Employment - ASCO
Consulting or Advisory Role - Bayer; Eisai; Ferring
 
Pam K. Mangat
No Relationships to Disclose
 
Eddy Shih-Hsin Yang
Consulting or Advisory Role - AstraZeneca; Strata Oncology
Research Funding - Clovis Oncology (Inst); Lilly (Inst); Novartis (Inst)
Other Relationship - Strata Oncology
 
Elie G. Dib
No Relationships to Disclose
 
Earle Frederick Burgess
Stock and Other Ownership Interests - Becton Dickinson; Calithera Biosciences; Clovis Oncology; Exelixis; Gilead Sciences; Medtronic
Honoraria - Bayer; Exelixis
Consulting or Advisory Role - Johnson & Johnson
Speakers' Bureau - Exelixis; Janssen
Research Funding - Astellas Pharma; Pfizer
Travel, Accommodations, Expenses - Exelixis; Roche/Genentech
 
Michael Howard Zakem
No Relationships to Disclose
 
Nitin Rohatgi
Honoraria - Eisai; Lilly; Puma Biotechnology
Speakers' Bureau - Eisai; Lilly; Puma Biotechnology
 
Mehmet Asim Bilen
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; Seagen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Incyte (Inst); Nektar (Inst); Peleton (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
Sasha L. Warren
No Relationships to Disclose
 
Sarah T. Anderson
No Relationships to Disclose
 
Andrew Lawrence Rygiel
No Relationships to Disclose
 
Richard L. Schilsky
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Varian Medical Systems